On October 10, 2025, VolitionRx Ltd filed an 8-K revealing an underwriting agreement for a public offering of 11,550,000 shares at $0.52 each, expected to raise approximately $5.4 million for research and product development. The offering closed on October 14, 2025, with estimated cash and cash equivalents at $0.3 million as of September 30, 2025.